Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer

Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer

Background: We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC-1) gene could be more genetically instable and consequently more responsive to a programmed cell de...

Full description

Bibliographic Details
Main Authors: Marco Maria Aiello, Cinzia Solinas, Matteo Santoni, Nicola Battelli, Nunzio Restuccia, Fiorenza Latteri, Sabrina Paratore, Francesco Verderame, Giuseppina Valeria Albanese, Paolo Bruzzi, Hector Josè Soto Parra
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
NSCLC
ERCC-1
SNP
C8092A
nivolumab
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01167/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01167/full

Similar Items